prescription pill designed for senior dogs that targets the metabolic drivers of aging. The company has raised over $150 million in funding and conducted the largest clinical trial in veterinary medicine history, enrolling 1,300 dogs across 70 clinics. The U.S. Food and Drug Administration has already cleared the drug on both safety and reasonable expectation of effectiveness, putting Loyal on course to launch commercially as soon as 2027 at approximately $100 per month.
The drug does not promise immortality. Instead, it aims to extend the healthy, active years of a dog’s life — slowing the biological clock rather than stopping it.
A stepping stone for human longevity research
Halioua’s ambitions extend well beyond the veterinary market. Dogs age rapidly compared to humans, making them ideal candidates for longevity trials — results that take decades to observe in people can surface in just a few years in canines. Federal approval pathways for animal drugs are also significantly faster than those for human medicines. If LOY-002 safely adds healthy years to dogs’ lives, it could serve as the longevity industry’s first FDA-approved proof of concept, potentially accelerating the path to similar treatments for humans.
The global longevity industry is currently valued at around $10 billion, attracting intense interest from biotech investors and researchers. Loyal’s work puts it at the frontier of that space — using man’s best friend as both the subject and the proof point for a new era of aging science.